Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

About Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at HCPLive.com/Clinical/Endocrinology (http://HCPLive.com/Clinical/Endocrinology). Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.

Publisher

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Category

health & fitness · science · technology

Language

en

Explicit

No

First episode

31 Jul 2020

Latest episode

24 Sept 2026

Latest episodes

1 of 215 episodes have a transcript.

1. 

   24 Sept 2026

   Weekly Insulin Efsitora Alfa Gets FDA Approval for Type 2 Diabetes

   On this episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, FNP-BC, talk through the latest addition to the weekly basal insulin landscape and what it means for clinicians starting or switching patients. Their conversation centers on real-world considerations for bringing a new insulin option into practice. Watch the video and get the full description: https://www.hcplive.com/view/diabetes-dialogue-weekly-insulin-efsitora-alfa-gets-fda-approval-for-type-2-diabetes (https://www.hcplive.com/view/diabetes-dialogue-weekly-insulin-efsitora-alfa-gets-fda-approval-for-type-2-diabetes) #Diabetes (https://www.youtube.com/hashtag/diabetes) #Endocrinology (https://www.youtube.com/hashtag/endocrinology) #DiabetesDialogue (https://www.youtube.com/hashtag/diabetesdialogue)

2. 

   18 Sept 2026

   Finerenone Approved for CKD in Type 1 Diabetes

   Chronic kidney disease remains a persistent risk for people with type 1 diabetes, with roughly 30% of this population in the US developing the complication despite optimized glucose, blood pressure, and lipid management. Until now, no therapy directly targeted the mineralocorticoid receptor pathway implicated in this progression for this group. On a recent episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed the US FDA approval of finerenone (Kerendia) for chronic kidney disease associated with type 1 diabetes. The approval marks the first new therapy in 30 years for this population and represents the third indication for finerenone, following its approvals for chronic kidney disease with type 2 diabetes in 2025 and for heart failure with left ventricular ejection fraction above 40%. Regulators granted priority review, and the decision draws on a broader evidence base spanning roughly 20,000 patients across five pivotal phase 3 trials of the nonsteroidal mineralocorticoid receptor antagonist class. The phase 3 FINE-ONE trial, a randomized, placebo-controlled, double-blind study, enrolled 242 adults with type 1 diabetes across nine countries and 80 sites and supported the approval. Finerenone added to standard of care reduced urine albumin-to-creatinine ratio (UACR) by 25% from baseline over six months compared with placebo. Overall, 68.1% of participants receiving finerenone achieved a UACR reduction of at least 30%, versus 46.6% with placebo, a threshold the American Diabetes Association associates with slowed CKD progression. Finerenone carries a risk of hyperkalemia, requiring potassium monitoring, and should not be combined with steroidal mineralocorticoid receptor antagonists such as spironolactone or with concurrent ACE inhibitor and angiotensin receptor blocker therapy. Unlike SGLT2 inhibitors, which remain unapproved in type 1 diabetes due to concerns about euglycemic diabetic ketoacidosis, finerenone offers clinicians a mechanistically distinct option with a defined safety profile in this population. The approval also renews attention on UACR screening, which remains underused in primary care despite annual screening recommendations for all patients with diabetes. Broader adoption of routine screening, paired with earlier mineralocorticoid receptor antagonist initiation, may extend the renoprotective gains demonstrated in FINE-ONE to more patients with type 1 diabetes.

3. 

   15 Sept 2026

   Beta Bionics Mint Patch Pump Gains FDA Clearance

   Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' FDA-cleared Mint patch pump and its potential to expand automated insulin delivery access.

Inside a recent episode

FDA Approves Semaglutide (Wegovy) for MASH

Published 22 Aug 2025 · Transcript excerpt

[…] And so it's so good. This raising awareness on this, because it is like the silent, I don't know if I should say silent killer, but it's just like silent condition that people aren't aware they have. Well, and I think that's really important. I think we need to understand what mash or muscle D is, right? It's a progressive disease that can lead to liver cirrhosis, right? Hepatic decompensation, liver cancer, liver transplantation, or death. So you're right. This is not just, OK, you have fatty liver. OK, you have no no. This is a progressive disease that actually shortens life expectancy. So the thing about semagletyde, the beauty of it, is that it's also indicated to reduce cardiovascular risk, right? […]

Who has been a guest on Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Names identified in recent episode analyses. Showing up to five guests.

• Casey Halpern
• Eden Miller
• Davida Kruger
• Rachael Sood
• Jay Shubrook

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

4.5 / 5

19 ratings

Spotify

5.0 / 5

5 ratings

Podcast Authority Score: 62 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

94

Social presence

0

YouTube

0

Engagement

77

Contact Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.

Shows with a similar audience

• 

  Diabetes Core Update

• 

  Juicebox Podcast: Type 1 Diabetes

• 

  Docs Who Lift

• 

  The Huddle: Conversations with the Diabetes Care Team

• 

  Fat Science

• 

  The Doctor's Farmacy with Mark Hyman, M.D.

Questions about Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives